Replies to post #222221 on Biotech Values

[DewDiligence]

ABBV/ENTA—The GT3-cirrhotic cohort is still in progress, according to today’s PR (in your post).

If it turns out that 8 weeks of Mavyret suffices for cirrhotic patients of any genotype, it will be quite a coup for ABBV/ENTA.